Grey Matters Health Inc. is a Canadian healthcare company primarily focused on the establishment of a new national network of dedicated brain PET scanning clinics in the U.S. under the NovaScan Neuroimaging Clinics™ brand, for the early-stage detection of AD and other forms of dementia, as well as epilepsy, neuro-oncology, and movement disorders including Parkinson’s disease.
Grey Matters Health is also the parent company of Algernon NeuroScience, a wholly owned subsidiary, that has been advancing a psychedelic program investigating a proprietary form of DMT for stroke and traumatic brain injury recovery, and has a drug development program for Repirinast, a repurposed drug for CKD. The Company’s chronic cough drug Ifenprodil, which works by stopping cough in the brain, was sold for USD $2M cash and a 20% equity position in Seyltx Inc., a private U.S. based drug development company that continues to advance research on the drug.
